earnings
confidence high
sentiment neutral
materiality 0.80
Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%
REGENERON PHARMACEUTICALS, INC.
2025-Q2 EPS reported
$20.02
revenue$6,704,300,000
- Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).
- Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.
- FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.
- EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.
- In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared.
item 2.02item 9.01